Strata Oncology Announces Medicare Coverage of StrataNGS Comprehensive Genomic Profiling Test for Patients with Advanced Solid Tumors

ANN ARBOR, Mich., Oct. 27, 2020 /PRNewswire/ -- Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), has established coverage of the StrataNGS™ test for patients with advanced stages (III or IV), recurrent, relapsed, refractory, and/or metastatic solid tumors.

StrataNGS is a comprehensive genomic profiling (CGP) test that features leading performance on small tumor tissue samples. The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.

A recent study presented at the 2020 Annual Meeting of the American Society of Clinical Oncology (ASCO) showed that the performance of StrataNGS on small tumor tissue samples may enable access to testing for more than double the number of patients compared to other leading comprehensive genomic profiling (CGP) tests. The results from an analysis of data collected in the Strata Trial demonstrated that only 43 percent of >20,000 consecutive tumor tissue samples received for CGP met tissue surface area requirements for leading commercial hybrid-capture-CGP tests. StrataNGS, a PCR-CGP test, delivered reportable results in 93 percent of all samples received.

"Medicare coverage of StrataNGS is an important milestone toward enabling broader access to comprehensive genomic profiling for patients with cancer," said Dan Rhodes, Ph.D., co-founder and CEO of Strata Oncology. "Tumor tissue availability is a major barrier to test access. With industry-low tumor tissue requirements, StrataNGS expands the number of patients that can receive tissue-based molecular profiling and potentially benefit from biomarker-guided targeted and immunotherapies."

StrataNGS has been available to patients as part of the Strata Trial, an observational trial conducted by Strata Oncology at over 125 hospitals nationwide. The company will continue to focus on its health system network before pursuing a broader commercial launch in 2021.

About StrataNGS™
StrataNGS is a comprehensive genomic profiling (CGP) test that features leading performance on small tumor tissue samples (>0.5mm² surface area). The 429-gene assay is performed on co-isolated RNA and DNA. Single-/multi-nucleotide variants (SNVs), short insertions and deletions (indels), copy number alterations (CNAs; amplifications and deep deletions), microsatellite instability (MSI) status, gene fusions, and tumor mutation burden (TMB) are assessed simultaneously.

About Strata Oncology
Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and pharma companies. Strata empowers health systems to deliver a cost-effective, system-wide, precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visit www.strataoncology.com. 

Strata Inquiries:
Renee Volpini
(917) 923-8117
[email protected]

SOURCE Strata Oncology, Inc.

Related Links

https://www.strataoncology.com